For nearly 25 years, Roche has been at the forefront of innovating companion diagnostics (CDx) that hold the power to transform patients’ lives by providing essential information that informs clinical decision-making and guides personalized treatment strategies.
With a steady pipeline of high medical value predictive tests fueled by collaborations with over 85 pharmaceutical partners, we deliver diagnostic certainty through the broadest menu of immunohistochemistry/in situ hybridization (IHC/ISH) companion diagnostics available today.1 We empower pathology professionals to consistently deliver reliable, timely results so that clinicians can make the right therapeutic decisions more quickly and offer more hope to patients and their loved ones.
We are committed to ongoing innovation that changes healthcare standards. Our goal is to take customers further on their journey to maximize their impact on patients by linking diagnoses with more personalized options and improved outcomes.
Over the last two decades, Roche has worked with over 200 pharmaceutical and biotechnology companies to deliver companion diagnostic tests that help enable greater patient access to novel cancer drugs. As a pioneer in personalized healthcare, we offer a leading-edge menu that helps connect patients with more innovative and targeted therapies, across more cancers, than any other IHC/ISH provider.1
Seamlessly integrated with the Roche pathology lab solution, our companion diagnostic portfolio leverages the latest in digital pathology and artificial intelligence (AI)-enabled image analysis technology. Together with our leadership in staining automation, lab integration, and digitization, we empower pathology labs to break down the barriers they face every day and accelerate their path to success.
To ensure more patients get the right treatment at the right time, clinicians, labs, and pathologists trust Roche to help them enable personalized healthcare through our market-leading portfolio of high medical value IHC/ISH assays, including companion diagnostics (CDx). Our fully optimized assay system combined with a rigorous development discipline sets us apart among laboratories and pathologists who rely on Roche quality to deliver critical, actionable insights.3
Our expertise and proven track record of success in launching companion diagnostics globally over nearly 25 years has established us as the diagnostic partner of choice for pharmaceutical companies bringing innovative new therapies to patients.
Roche companion diagnostics are helping to improve outcomes for patients like Enisa Besic. Thanks to groundbreaking innovation in precision therapeutics and biomarker testing, Enisa was eligible for a new treatment to combat what’s known as human epidermal growth factor receptor 2 (HER2)-low breast cancer. Hear her speak about her personal journey.
We are dedicated to helping pathologists stay at the forefront of diagnostics and advancing their skills through comprehensive education and training. We offer a suite of tools developed by our in-house pathologists, including online courses and videos to aid in the interpretation of our assays.
We believe that precision medicine can radically improve lives. That’s why we focus on delivering solutions to advance your therapeutic pipeline at every stage. Roche has worked with 200 biopharma companies to develop and commercialize tests that help enable patient access to novel cancer drugs.
References:
